0
₹0 0
Nextgen Biotech

Call us:

menu

Erlocip 150mg - Erlotinib Tablets

  • Home
  • Erlocip 150mg - Erlotinib Tablets

Erlocip 150mg - Erlotinib Tablets

Erlocip 150mg contains Erlotinib, a targeted oral anticancer therapy primarily used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by inhibiting EGFR (epidermal growth factor receptor), thereby slowing or stopping cancer cell growth and proliferation.

Select your size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Erlotinib
Brand Name: Erlocip
Packing: Strip of 30 tablets
Strength: 150mg per tablet
Manufacturer: Cipla Ltd.
Form: Oral tablets
Category: Antineoplastic Agent / Tyrosine Kinase Inhibitor
Product Intro:
Erlocip 150mg is a high-strength formulation of Erlotinib, a tyrosine kinase inhibitor (TKI) that specifically targets EGFR mutations in cancer cells. Manufactured by Cipla Ltd., Erlocip is commonly prescribed for advanced or metastatic NSCLC, especially in patients with known EGFR mutations, and in combination with gemcitabine for pancreatic cancer.
Uses:
  1. Non-Small Cell Lung Cancer (NSCLC) – with EGFR exon 19 or exon 21 mutations
  2. Pancreatic Cancer – in combination with gemcitabine
  3. Maintenance therapy in NSCLC following initial treatment response
  4. Recurrent/metastatic NSCLC after failure of chemotherapy
  5. Off-label use in other EGFR-expressing solid tumors under clinical guidance
  6. Targeted monotherapy in patients unfit for conventional chemotherapy
Storage Instructions:
  1. Store at 15°C to 30°C (59°F to 86°F)
  2. Keep away from heat, moisture, and direct sunlight
  3. Store in the original packaging
  4. Keep out of reach of children
How it Works (Mechanism of Action):
Erlotinib works by selectively inhibiting the tyrosine kinase activity of the EGFR, a receptor involved in the regulation of cell growth and division. By blocking EGFR signaling, it prevents tumor cell proliferation and survival, particularly in cancers driven by EGFR gene mutations.
Side Effects:
Common Side Effects:
  1. Rash or acneiform eruptions
  2. Diarrhea
  3. Fatigue
  4. Nausea and vomiting
  5. Anorexia
  6. Mouth sores
  7. Dry skin
Serious Side Effects:
  1. Interstitial lung disease (ILD) – rare but potentially fatal
  2. Hepatotoxicity – monitor liver function
  3. GI perforation – rare but life-threatening
  4. Severe skin reactions (e.g., Stevens-Johnson syndrome)
  5. Eye disorders – keratitis, corneal ulceration
Dosage (Typical Recommended Dose):
  1. NSCLC: 150mg orally once daily
  2. Pancreatic Cancer: 100mg daily (lower dose), in combination with gemcitabine
  3. Dose adjustments may be required based on side effects or hepatic impairment
Method of Administration:
  1. Take orally with a glass of water
  2. Should be taken at least 1 hour before or 2 hours after food
  3. Do not crush, chew, or split the tablet
  4. Take at the same time every day
Precautions:
  1. Test for EGFR mutation status before initiating therapy
  2. Avoid use in patients with severe hepatic or renal impairment unless necessary
  3. Monitor for signs of lung disease, liver toxicity, and severe diarrhea
  4. Advise use of sunscreen and protective clothing for photosensitivity
  5. Smoking decreases Erlotinib levels – cessation is highly recommended
Drug Interactions:
  1. Proton Pump Inhibitors (PPIs) – reduce Erlotinib absorption
  2. CYP3A4 inhibitors (e.g., ketoconazole) – increase toxicity risk
  3. CYP3A4 inducers (e.g., rifampicin, phenytoin) – reduce effectiveness
  4. Warfarin – may increase bleeding risk; monitor INR
  5. Smoking – induces metabolism and reduces drug levels
Allergies:
  1. Contraindicated in individuals with hypersensitivity to Erlotinib or formulation ingredients
  2. Watch for signs of allergic reaction:
    1. Skin rash
    2. Swelling of face or tongue
    3. Breathing difficulty
    4. Severe itching or dizziness
Overdose Information:
  1. Symptoms: Severe diarrhea, rash, hepatic dysfunction
  2. Management: Provide symptomatic and supportive treatment
  3. No known antidote – hospital monitoring may be required
Missed Dose Instructions:
  1. Take the missed dose as soon as remembered unless close to the next dose
  2. If it's almost time for the next dose, skip the missed dose
  3. Do not double up to compensate for a missed dose
Additional Notes:
  1. Avoid grapefruit and grapefruit juice during treatment
  2. Regularly monitor liver enzymes, pulmonary status, and skin condition
  3. Educate patient on signs of serious adverse reactions
  4. Encourage hydration and good skin care to manage rash and dryness
  5. Smoking cessation is essential for maintaining drug effectiveness
View More

In The Same Category

Cart